Imatinib (brand name Gleevec) is a kinase inhibitor acting against Abelson tyrosine kinase BCR–ABL, the KIT and PDGF receptors and is used for therapy of chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST) and several other malignancies (88). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.